MedTrace Logo

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

NCT06415669 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-05-29

No results posted yet for this study

Summary

To evaluate the initial efficacy and safety of paclitaxel for injection (albumin-bound) in combination with apatinib mesylate and adebrelimab in the treatment of locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma following the progression of previous immunotherapy.

Conditions

  • Gastric/Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

Paclitaxel for injection (albumin-bound)

100 mg/m2, day 1, day 8, every 21 days for a cycle.

DRUG

Adebrelimab

20mg/kg or 1200mg, the first day, every 21 days as a cycle.

DRUG

Apatinib mesylate

250mg once a day for 5 consecutive days and discontinue for 2 days

Sponsors & Collaborators

  • The First Affiliated Hospital of Xiamen University

    lead OTHER

Principal Investigators

  • Mingquan Cai · The First Affiliated Hospital of Xiamen University

  • Xia Lv · Xiamen Humanity Hospital

  • Jun Qiu · Xiamen Humanity Hospital

  • Huita Wu · Zhongshan Hospital Affiliated to Xiamen University

  • Xiuping Zhang · Zhongshan Hospital (Xiamen), Fudan University

  • Xiaojian Yin · Xiamen Changgeng Hospital

  • Jinfeng Zhu · Quanzhou First Hospital

  • Wen Chen · The Second Affiliated Hospital of Fujian Medical University

  • Yijun Wang · Zhangzhou Hospital

  • Guoqin Qiu · The 73rd Army Hospital

  • Yongmei Liu · West China Xiamen Hospital of Sichuan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-19
Primary Completion
2026-05-19
Completion
2027-05-19

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06415669 on ClinicalTrials.gov